Freestone Grove Partners LP Viking Therapeutics, Inc. Transaction History
Freestone Grove Partners LP
- $8.16 Trillion
- Q4 2024
A detailed history of Freestone Grove Partners LP transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Freestone Grove Partners LP holds 5,572 shares of VKTX stock, worth $176,242. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,572Holding current value
$176,242% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding VKTX
# of Institutions
466Shares Held
65.8MCall Options Held
5.84MPut Options Held
3.76M-
Vanguard Group Inc Valley Forge, PA10.2MShares$322 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$191 Million0.01% of portfolio
-
State Street Corp Boston, MA4.93MShares$156 Million0.01% of portfolio
-
Morgan Stanley New York, NY2.59MShares$82 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.16MShares$68.2 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $2.43B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...